Are there any generic versions of Upadatinib available in the Indian market? What's the price?

Upadacitinib (Upadacitinib) is an oral Janus kinase (JAK) inhibitor, mainly used to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis and atopic dermatitis. Due to the high prices of brand-name drugs, many patients are facing financial pressure, so the demand for their generic drugs is increasing.

Currently, there are no generic versions of upadatinib available in the Indian market. This situation has troubled patients who rely on the drug for long-term treatment. Although India has a good reputation for generic drug production, generic versions of upapatinib have not yet emerged due to various factors such as patent protection and pharmaceutical policy restrictions.

But in other countries, generic versions of upadatinib are already on the market. For example, there is a generic version produced by Lucius Pharmaceuticals on the market in Laos, with a specification of 15 mg × 30 tablets and a price of about 500 to 600 yuan per box. This is a significantly lower price than the original drug, providing patients with a more economical choice. In addition, the generic drug has been approved by the Lao Ministry of Health, which guarantees its quality.

At the same time, Bangladesh's Yaopin International has also launched a generic version of upadatinib with the same specifications, with a slightly higher price, about between 700 and 800 yuan. This manufacturer has a high reputation and the quality of the drugs it produces is also guaranteed.

When choosing a drug, in addition to price, patients should also pay attention to the quality and source of the drug. When purchasing generic drugs, be sure to do so through reputable and formal channels to ensure the safety and effectiveness of the drug.

In summary, although there are currently no generic versions of upadatinib available in India, generic versions are available in other countries at relatively low prices, providing patients with more treatment options.

References:

https://www.drugs.com/history/rinvoq.html

xa0